Tenaya Therapeutics up as heart disorder drug gets 'orphan' designation
** Shares of drug developer Tenaya Therapeutics Inc TNYA.O
jump 4% to $2.6 premarket
** U.S. FDA grants orphan drug designation for TNYA's gene
therapy candidate to treat patients with rare heart disease,
arrhythmogenic right ventricular cardiomyopathy urn:newsml:reuters.com:*:nGNX6nWMHl
** FDA awards "orphan" status to drugs that treat rare
conditions and are protected through a series of government
incentives once they reach the market
** As of Friday's close, company's shares down ~87% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027